

# Laleh Majlessi

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/1748199/publications.pdf](https://exaly.com/author-pdf/1748199/publications.pdf)

Version: 2024-02-01

30  
papers

2,857  
citations

313897

21  
h-index

445597

30  
g-index

36  
all docs

36  
docs citations

36  
times ranked

3368  
citing authors

#	ARTICLE	IF	CITATIONS
1	Full-Lung Prophylaxis against SARS-CoV-2 by One-Shot or Booster Intranasal Lentiviral Vaccination in Syrian Golden Hamsters. <i>Vaccines</i> , 2023, 11, 12.	4.5	1
2	Full eradication of pre-clinical human papilloma virus-induced tumors by a lentiviral vaccine. <i>EMBO Molecular Medicine</i> , 2023, 15, .	7.3	3
3	An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa. <i>Molecular Therapy</i> , 2022, 30, 2984-2997.	8.1	20
4	A lentiviral vector encoding fusion of light invariant chain and mycobacterial antigens induces protective CD4+ T cell immunity. <i>Cell Reports</i> , 2022, 40, 111142.	6.3	9
5	Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models. <i>Cell Host and Microbe</i> , 2021, 29, 236-249.e6.	11.0	115
6	Lentiviral vector induces high-quality memory T cells via dendritic cells transduction. <i>Communications Biology</i> , 2021, 4, 713.	4.5	21
7	Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice. <i>EMBO Molecular Medicine</i> , 2021, 13, e14459.	7.3	27
8	Use of lentiviral vectors in vaccination. <i>Expert Review of Vaccines</i> , 2021, 20, 1571-1586.	4.5	19
9	Un candidat vaccin lentiviral anti-Covid-19 administrable par voie intranasale. <i>Medecine/Sciences</i> , 2021, 37, 1172-1175.	0.2	4
10	Intrinsic Antibacterial Activity of Nanoparticles Made of $\beta$ -Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis. <i>ACS Nano</i> , 2019, 13, 3992-4007.	15.3	46
11	Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: an Efficient Strategy to Treat Intracellular Infections. <i>Particle and Particle Systems Characterization</i> , 2019, 36, 1800360.	2.5	24
12	Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors. <i>Cell Reports</i> , 2018, 23, 1072-1084.	6.3	30
13	Unexpected Genomic and Phenotypic Diversity of Mycobacterium africanum Lineage 5 Affects Drug Resistance, Protein Secretion, and Immunogenicity. <i>Genome Biology and Evolution</i> , 2018, 10, 1858-1874.	2.6	51
14	RD5-mediated lack of PE_PGRS and PPE-MPTR export in BCG vaccine strains results in strong reduction of antigenic repertoire but little impact on protection. <i>PLoS Pathogens</i> , 2018, 14, e1007139.	4.1	39
15	Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection. <i>Cell Reports</i> , 2017, 18, 2752-2765.	6.3	102
16	Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles. <i>Scientific Reports</i> , 2017, 7, 5390.	3.4	76
17	CD4+ T Cells Recognizing PE/PPE Antigens Directly or via Cross Reactivity Are Protective against Pulmonary Mycobacterium tuberculosis Infection. <i>PLoS Pathogens</i> , 2016, 12, e1005770.	4.1	50
18	Perspectives on mycobacterial vacuole-to-cytosol translocation: the importance of cytosolic access. <i>Cellular Microbiology</i> , 2016, 18, 1070-1077.	2.3	26

#	ARTICLE	IF	CITATIONS
19	ESX secretion systems: mycobacterial evolution to counter host immunity. <i>Nature Reviews Microbiology</i> , 2016, 14, 677-691.	29.2	322
20	Release of mycobacterial antigens. <i>Immunological Reviews</i> , 2015, 264, 25-45.	6.1	82
21	Ecto-5'-Nucleotidase (CD73) Deficiency in Mycobacterium tuberculosis-Infected Mice Enhances Neutrophil Recruitment. <i>Infection and Immunity</i> , 2015, 83, 3666-3674.	2.4	16
22	Strong Immunogenicity and Cross-Reactivity of Mycobacterium tuberculosis ESX-5 Type VII Secretion-Encoded PE-PPE Proteins Predicts Vaccine Potential. <i>Cell Host and Microbe</i> , 2012, 11, 352-363.	11.0	103
23	Disruption of the ESX-5 system of <i>Mycobacterium tuberculosis</i> causes loss of PPE protein secretion, reduction of cell wall integrity and strong attenuation. <i>Molecular Microbiology</i> , 2012, 83, 1195-1209.	2.5	180
24	Control of M. tuberculosis ESAT-6 Secretion and Specific T Cell Recognition by PhoP. <i>PLoS Pathogens</i> , 2008, 4, e33.	4.1	238
25	An Increase in Antimycobacterial Th1-Cell Responses by Prime-Boost Protocols of Immunization Does Not Enhance Protection against Tuberculosis. <i>Infection and Immunity</i> , 2006, 74, 2128-2137.	2.4	95
26	High Frequency of CD4+ T Cells Specific for the TB10.4 Protein Correlates with Protection against Mycobacterium tuberculosis Infection. <i>Infection and Immunity</i> , 2006, 74, 3396-3407.	2.4	88
27	Dissection of ESAT-6 System 1 of Mycobacterium tuberculosis and Impact on Immunogenicity and Virulence. <i>Infection and Immunity</i> , 2006, 74, 88-98.	2.4	286
28	Functional Analysis of Early Secreted Antigenic Target-6, the Dominant T-cell Antigen of Mycobacterium tuberculosis, Reveals Key Residues Involved in Secretion, Complex Formation, Virulence, and Immunogenicity. <i>Journal of Biological Chemistry</i> , 2005, 280, 33953-33959.	3.5	140
29	Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. <i>Nature Medicine</i> , 2003, 9, 533-539.	30.1	576
30	CD8 + -T-Cell Responses of Mycobacterium-Infected Mice to a Newly Identified Major Histocompatibility Complex Class I-Restricted Epitope Shared by Proteins of the ESAT-6 Family. <i>Infection and Immunity</i> , 2003, 71, 7173-7177.	2.4	52